| 1 | ( | 2,178,814 |
| 2 | nonphytate | 9 |
| 3 | 0.63/100 | 3 |
| 4 | injection-treated | 3 |
| 5 | naocl-mta | 3 |
| 6 | 485.7 | 2 |
| 7 | a-poly | 2 |
| 8 | abortus-treated | 2 |
| 9 | ematologia | 2 |
| 10 | glucose+lipids | 2 |
| 11 | nmol·min/l | 2 |
| 12 | pycc | 2 |
| 13 | +11.85 | 1 |
| 14 | -0.22±0.87 | 1 |
| 15 | -1.06±1.4 | 1 |
| 16 | -1.08±1.04 | 1 |
| 17 | -1/k | 1 |
| 18 | -1and | 1 |
| 19 | -3-oxoprop- | 1 |
| 20 | -4,4'-biphenylene | 1 |
| 21 | -dimethylamino | 1 |
| 22 | -vasc-score | 1 |
| 23 | /pai | 1 |
| 24 | 0.05/100 | 1 |
| 25 | 0.1-46.1 | 1 |
| 26 | 0.189+/-0.074 | 1 |
| 27 | 0.3869 | 1 |
| 28 | 0.47/100 | 1 |
| 29 | 0.73/100 | 1 |
| 30 | 0.76/100 | 1 |
| 31 | 0.85-3.60 | 1 |
| 32 | 1.023-1.040 | 1 |
| 33 | 1.08-146.5 | 1 |
| 34 | 1.41-4.22 | 1 |
| 35 | 1.80-3.05 | 1 |
| 36 | 1.90-4.96 | 1 |
| 37 | 1/fv | 1 |
| 38 | 10mg/kg/day+imidapril | 1 |
| 39 | 11.90±1.17 | 1 |
| 40 | 13475 | 1 |
| 41 | 14.9-40.3 | 1 |
| 42 | 15,14 | 1 |
| 43 | 16″ | 1 |
| 44 | 2.51±0.81 | 1 |
| 45 | 2.82±1.14 | 1 |
| 46 | 22.5/100 | 1 |
| 47 | 26.6+/-10.5 | 1 |
| 48 | 28.8-588.6 | 1 |
| 49 | 38.0-39.8 | 1 |
| 50 | 3d/o | 1 |
| 51 | 4-hy-droxy-but-2-ynyl | 1 |
| 52 | 4.33/100 | 1 |
| 53 | 446.2/day | 1 |
| 54 | 45.5±8.9 | 1 |
| 55 | 4g/4g/pai | 1 |
| 56 | 5.5/1,000 | 1 |
| 57 | 5.61/100 | 1 |
| 58 | 500-mg-bid | 1 |
| 59 | 55-24 | 1 |
| 60 | 56,6 | 1 |
| 61 | 5:5:4:6 | 1 |
| 62 | 6,931 | 1 |
| 63 | 72.3+/-13.9 | 1 |
| 64 | 8-18.9 | 1 |
| 65 | 80474-14-2/cas | 1 |
| 66 | 9-200 | 1 |
| 67 | 9.1+/- | 1 |
| 68 | 9.2-11.3 | 1 |
| 69 | 9/btub | 1 |
| 70 | 9050 | 1 |
| 71 | 98.6+/-9.7 | 1 |
| 72 | a2008 | 1 |
| 73 | absolute/atm | 1 |
| 74 | achievedafter | 1 |
| 75 | activi | 1 |
| 76 | actrn12613000637741 | 1 |
| 77 | adaptação | 1 |
| 78 | adrenaline/30mg | 1 |
| 79 | amloidipine | 1 |
| 80 | animais | 1 |
| 81 | antagoinst | 1 |
| 82 | ante-/post-partum | 1 |
| 83 | antigen/parasite | 1 |
| 84 | anéis | 1 |
| 85 | arsénio | 1 |
| 86 | b-ht | 1 |
| 87 | bcli- | 1 |
| 88 | bibliografia | 1 |
| 89 | bp/d2 | 1 |
| 90 | ca-al | 1 |
| 91 | ca-hmb | 1 |
| 92 | can48.00-dollars | 1 |
| 93 | characteriz | 1 |
| 94 | chd-derived | 1 |
| 95 | chepu | 1 |
| 96 | chizukit | 1 |
| 97 | ci-€315 | 1 |
| 98 | clevios | 1 |
| 99 | colecistectomia | 1 |
| 100 | courses/1000 | 1 |
| 101 | deficiency-mediated | 1 |
| 102 | deoxygenates | 1 |
| 103 | detection-to | 1 |
| 104 | difference-comparing | 1 |
| 105 | dihdyroxy | 1 |
| 106 | dilatation/elevated | 1 |
| 107 | ecografia | 1 |
| 108 | epoxyketone-based | 1 |
| 109 | equivalents-eq-of | 1 |
| 110 | explantations/two | 1 |
| 111 | fe3-x | 1 |
| 112 | gags/mmol | 1 |
| 113 | giacco | 1 |
| 114 | gm/2 | 1 |
| 115 | group-ag | 1 |
| 116 | group-rg | 1 |
| 117 | group=group | 1 |
| 118 | h-clean-up | 1 |
| 119 | haplo | 1 |
| 120 | hzi | 1 |
| 121 | hēi | 1 |
| 122 | impairment-induced | 1 |
| 123 | induc | 1 |
| 124 | instru | 1 |
| 125 | invega® | 1 |
| 126 | isrcnt | 1 |
| 127 | isys | 1 |
| 128 | loro | 1 |
| 129 | malnutrition/ | 1 |
| 130 | melanoplus | 1 |
| 131 | memb | 1 |
| 132 | metalaxyl-m | 1 |
| 133 | mg+l-thyroxine→2.5 | 1 |
| 134 | ml.min-1.kg | 1 |
| 135 | ml·kg- | 1 |
| 136 | mofetil-induced | 1 |
| 137 | more-extensive | 1 |
| 138 | network/id | 1 |
| 139 | nmole/mg | 1 |
| 140 | paciente | 1 |
| 141 | pmole/mg | 1 |
| 142 | population.s | 1 |
| 143 | population♂×my | 1 |
| 144 | post-triton | 1 |
| 145 | primitif | 1 |
| 146 | procedimento | 1 |
| 147 | protein.in | 1 |
| 148 | píng | 1 |
| 149 | rb51-infected | 1 |
| 150 | rca-cfr | 1 |
| 151 | rectal-axillary | 1 |
| 152 | recurrens | 1 |
| 153 | regulans | 1 |
| 154 | rene | 1 |
| 155 | responses.systemic | 1 |
| 156 | rs10841048 | 1 |
| 157 | rs11140653 | 1 |
| 158 | rs13225016 | 1 |
| 159 | rs4145836 | 1 |
| 160 | rs4975017 | 1 |
| 161 | rs9513070/rs9554320/rs9582036 | 1 |
| 162 | rv/pb | 1 |
| 163 | score/spine | 1 |
| 164 | sive | 1 |
| 165 | smoking,4±2 | 1 |
| 166 | speranskiae | 1 |
| 167 | sport/5.10b | 1 |
| 168 | stabi | 1 |
| 169 | sulphate/kg | 1 |
| 170 | test.for | 1 |
| 171 | theory-calibrated | 1 |
| 172 | tricam-p | 1 |
| 173 | u10 | 1 |
| 174 | ultivite | 1 |
| 175 | university-vancouver | 1 |
| 176 | vrp1®and | 1 |
| 177 | vs.0.42 | 1 |
| 178 | vs.day | 1 |
| 179 | wire-derived | 1 |
| 180 | wps/week | 1 |
| 181 | z800 | 1 |
| 182 | °s-57 | 1 |
| 183 | °s-58 | 1 |
| 184 | α3α4β2 | 1 |
| 185 | β=-0.093 | 1 |
| 186 | β=-0.113 | 1 |
| 187 | β=-0.114 | 1 |
| 188 | β=-0.143 | 1 |
| 1 | ( | 2,178,814 |
| 2 | +11.85 | 1 |
| 3 | -0.22±0.87 | 1 |
| 4 | -1.06±1.4 | 1 |
| 5 | -1.08±1.04 | 1 |
| 6 | -1/k | 1 |
| 7 | -1and | 1 |
| 8 | -3-oxoprop- | 1 |
| 9 | -4,4'-biphenylene | 1 |
| 10 | -dimethylamino | 1 |
| 11 | -vasc-score | 1 |
| 12 | /pai | 1 |
| 13 | 0.05/100 | 1 |
| 14 | 0.1-46.1 | 1 |
| 15 | 0.189+/-0.074 | 1 |
| 16 | 0.3869 | 1 |
| 17 | 0.47/100 | 1 |
| 18 | 0.63/100 | 3 |
| 19 | 0.73/100 | 1 |
| 20 | 0.76/100 | 1 |
| 21 | 0.85-3.60 | 1 |
| 22 | 1.023-1.040 | 1 |
| 23 | 1.08-146.5 | 1 |
| 24 | 1.41-4.22 | 1 |
| 25 | 1.80-3.05 | 1 |
| 26 | 1.90-4.96 | 1 |
| 27 | 1/fv | 1 |
| 28 | 10mg/kg/day+imidapril | 1 |
| 29 | 11.90±1.17 | 1 |
| 30 | 13475 | 1 |
| 31 | 14.9-40.3 | 1 |
| 32 | 15,14 | 1 |
| 33 | 16″ | 1 |
| 34 | 2.51±0.81 | 1 |
| 35 | 2.82±1.14 | 1 |
| 36 | 22.5/100 | 1 |
| 37 | 26.6+/-10.5 | 1 |
| 38 | 28.8-588.6 | 1 |
| 39 | 38.0-39.8 | 1 |
| 40 | 3d/o | 1 |
| 41 | 4-hy-droxy-but-2-ynyl | 1 |
| 42 | 4.33/100 | 1 |
| 43 | 446.2/day | 1 |
| 44 | 45.5±8.9 | 1 |
| 45 | 485.7 | 2 |
| 46 | 4g/4g/pai | 1 |
| 47 | 5.5/1,000 | 1 |
| 48 | 5.61/100 | 1 |
| 49 | 500-mg-bid | 1 |
| 50 | 55-24 | 1 |
| 51 | 56,6 | 1 |
| 52 | 5:5:4:6 | 1 |
| 53 | 6,931 | 1 |
| 54 | 72.3+/-13.9 | 1 |
| 55 | 8-18.9 | 1 |
| 56 | 80474-14-2/cas | 1 |
| 57 | 9-200 | 1 |
| 58 | 9.1+/- | 1 |
| 59 | 9.2-11.3 | 1 |
| 60 | 9/btub | 1 |
| 61 | 9050 | 1 |
| 62 | 98.6+/-9.7 | 1 |
| 63 | a-poly | 2 |
| 64 | a2008 | 1 |
| 65 | abortus-treated | 2 |
| 66 | absolute/atm | 1 |
| 67 | achievedafter | 1 |
| 68 | activi | 1 |
| 69 | actrn12613000637741 | 1 |
| 70 | adaptação | 1 |
| 71 | adrenaline/30mg | 1 |
| 72 | amloidipine | 1 |
| 73 | animais | 1 |
| 74 | antagoinst | 1 |
| 75 | ante-/post-partum | 1 |
| 76 | antigen/parasite | 1 |
| 77 | anéis | 1 |
| 78 | arsénio | 1 |
| 79 | b-ht | 1 |
| 80 | bcli- | 1 |
| 81 | bibliografia | 1 |
| 82 | bp/d2 | 1 |
| 83 | ca-al | 1 |
| 84 | ca-hmb | 1 |
| 85 | can48.00-dollars | 1 |
| 86 | characteriz | 1 |
| 87 | chd-derived | 1 |
| 88 | chepu | 1 |
| 89 | chizukit | 1 |
| 90 | ci-€315 | 1 |
| 91 | clevios | 1 |
| 92 | colecistectomia | 1 |
| 93 | courses/1000 | 1 |
| 94 | deficiency-mediated | 1 |
| 95 | deoxygenates | 1 |
| 96 | detection-to | 1 |
| 97 | difference-comparing | 1 |
| 98 | dihdyroxy | 1 |
| 99 | dilatation/elevated | 1 |
| 100 | ecografia | 1 |
| 101 | ematologia | 2 |
| 102 | epoxyketone-based | 1 |
| 103 | equivalents-eq-of | 1 |
| 104 | explantations/two | 1 |
| 105 | fe3-x | 1 |
| 106 | gags/mmol | 1 |
| 107 | giacco | 1 |
| 108 | glucose+lipids | 2 |
| 109 | gm/2 | 1 |
| 110 | group-ag | 1 |
| 111 | group-rg | 1 |
| 112 | group=group | 1 |
| 113 | h-clean-up | 1 |
| 114 | haplo | 1 |
| 115 | hzi | 1 |
| 116 | hēi | 1 |
| 117 | impairment-induced | 1 |
| 118 | induc | 1 |
| 119 | injection-treated | 3 |
| 120 | instru | 1 |
| 121 | invega® | 1 |
| 122 | isrcnt | 1 |
| 123 | isys | 1 |
| 124 | loro | 1 |
| 125 | malnutrition/ | 1 |
| 126 | melanoplus | 1 |
| 127 | memb | 1 |
| 128 | metalaxyl-m | 1 |
| 129 | mg+l-thyroxine→2.5 | 1 |
| 130 | ml.min-1.kg | 1 |
| 131 | ml·kg- | 1 |
| 132 | mofetil-induced | 1 |
| 133 | more-extensive | 1 |
| 134 | naocl-mta | 3 |
| 135 | network/id | 1 |
| 136 | nmole/mg | 1 |
| 137 | nmol·min/l | 2 |
| 138 | nonphytate | 9 |
| 139 | paciente | 1 |
| 140 | pmole/mg | 1 |
| 141 | population.s | 1 |
| 142 | population♂×my | 1 |
| 143 | post-triton | 1 |
| 144 | primitif | 1 |
| 145 | procedimento | 1 |
| 146 | protein.in | 1 |
| 147 | pycc | 2 |
| 148 | píng | 1 |
| 149 | rb51-infected | 1 |
| 150 | rca-cfr | 1 |
| 151 | rectal-axillary | 1 |
| 152 | recurrens | 1 |
| 153 | regulans | 1 |
| 154 | rene | 1 |
| 155 | responses.systemic | 1 |
| 156 | rs10841048 | 1 |
| 157 | rs11140653 | 1 |
| 158 | rs13225016 | 1 |
| 159 | rs4145836 | 1 |
| 160 | rs4975017 | 1 |
| 161 | rs9513070/rs9554320/rs9582036 | 1 |
| 162 | rv/pb | 1 |
| 163 | score/spine | 1 |
| 164 | sive | 1 |
| 165 | smoking,4±2 | 1 |
| 166 | speranskiae | 1 |
| 167 | sport/5.10b | 1 |
| 168 | stabi | 1 |
| 169 | sulphate/kg | 1 |
| 170 | test.for | 1 |
| 171 | theory-calibrated | 1 |
| 172 | tricam-p | 1 |
| 173 | u10 | 1 |
| 174 | ultivite | 1 |
| 175 | university-vancouver | 1 |
| 176 | vrp1®and | 1 |
| 177 | vs.0.42 | 1 |
| 178 | vs.day | 1 |
| 179 | wire-derived | 1 |
| 180 | wps/week | 1 |
| 181 | z800 | 1 |
| 182 | °s-57 | 1 |
| 183 | °s-58 | 1 |
| 184 | α3α4β2 | 1 |
| 185 | β=-0.093 | 1 |
| 186 | β=-0.113 | 1 |
| 187 | β=-0.114 | 1 |
| 188 | β=-0.143 | 1 |
| 1 | ( | 2,178,814 |
| 2 | 9.1+/- | 1 |
| 3 | ml·kg- | 1 |
| 4 | bcli- | 1 |
| 5 | -3-oxoprop- | 1 |
| 6 | malnutrition/ | 1 |
| 7 | 5.5/1,000 | 1 |
| 8 | courses/1000 | 1 |
| 9 | 5.61/100 | 1 |
| 10 | 4.33/100 | 1 |
| 11 | 0.63/100 | 3 |
| 12 | 0.73/100 | 1 |
| 13 | 22.5/100 | 1 |
| 14 | 0.05/100 | 1 |
| 15 | 0.76/100 | 1 |
| 16 | 0.47/100 | 1 |
| 17 | 9-200 | 1 |
| 18 | z800 | 1 |
| 19 | u10 | 1 |
| 20 | 1.023-1.040 | 1 |
| 21 | 9050 | 1 |
| 22 | 0.85-3.60 | 1 |
| 23 | 0.1-46.1 | 1 |
| 24 | 6,931 | 1 |
| 25 | actrn12613000637741 | 1 |
| 26 | 2.51±0.81 | 1 |
| 27 | gm/2 | 1 |
| 28 | 1.41-4.22 | 1 |
| 29 | vs.0.42 | 1 |
| 30 | bp/d2 | 1 |
| 31 | smoking,4±2 | 1 |
| 32 | α3α4β2 | 1 |
| 33 | 14.9-40.3 | 1 |
| 34 | 9.2-11.3 | 1 |
| 35 | β=-0.113 | 1 |
| 36 | β=-0.143 | 1 |
| 37 | rs11140653 | 1 |
| 38 | β=-0.093 | 1 |
| 39 | -1.06±1.4 | 1 |
| 40 | -1.08±1.04 | 1 |
| 41 | 15,14 | 1 |
| 42 | 2.82±1.14 | 1 |
| 43 | β=-0.114 | 1 |
| 44 | 55-24 | 1 |
| 45 | 0.189+/-0.074 | 1 |
| 46 | 26.6+/-10.5 | 1 |
| 47 | mg+l-thyroxine→2.5 | 1 |
| 48 | 1.08-146.5 | 1 |
| 49 | 1.80-3.05 | 1 |
| 50 | ci-€315 | 1 |
| 51 | 13475 | 1 |
| 52 | +11.85 | 1 |
| 53 | 56,6 | 1 |
| 54 | 28.8-588.6 | 1 |
| 55 | rs13225016 | 1 |
| 56 | rs9513070/rs9554320/rs9582036 | 1 |
| 57 | rs4145836 | 1 |
| 58 | 1.90-4.96 | 1 |
| 59 | 5:5:4:6 | 1 |
| 60 | 485.7 | 2 |
| 61 | 98.6+/-9.7 | 1 |
| 62 | 11.90±1.17 | 1 |
| 63 | rs4975017 | 1 |
| 64 | °s-57 | 1 |
| 65 | -0.22±0.87 | 1 |
| 66 | 38.0-39.8 | 1 |
| 67 | a2008 | 1 |
| 68 | rs10841048 | 1 |
| 69 | °s-58 | 1 |
| 70 | 72.3+/-13.9 | 1 |
| 71 | 8-18.9 | 1 |
| 72 | 45.5±8.9 | 1 |
| 73 | 0.3869 | 1 |
| 74 | ecografia | 1 |
| 75 | bibliografia | 1 |
| 76 | ematologia | 2 |
| 77 | colecistectomia | 1 |
| 78 | naocl-mta | 3 |
| 79 | sport/5.10b | 1 |
| 80 | memb | 1 |
| 81 | ca-hmb | 1 |
| 82 | rv/pb | 1 |
| 83 | 9/btub | 1 |
| 84 | pycc | 2 |
| 85 | responses.systemic | 1 |
| 86 | induc | 1 |
| 87 | mofetil-induced | 1 |
| 88 | impairment-induced | 1 |
| 89 | epoxyketone-based | 1 |
| 90 | injection-treated | 3 |
| 91 | abortus-treated | 2 |
| 92 | deficiency-mediated | 1 |
| 93 | theory-calibrated | 1 |
| 94 | dilatation/elevated | 1 |
| 95 | rb51-infected | 1 |
| 96 | chd-derived | 1 |
| 97 | wire-derived | 1 |
| 98 | network/id | 1 |
| 99 | 500-mg-bid | 1 |
| 100 | -1and | 1 |
| 101 | vrp1®and | 1 |
| 102 | speranskiae | 1 |
| 103 | -4,4'-biphenylene | 1 |
| 104 | rene | 1 |
| 105 | amloidipine | 1 |
| 106 | score/spine | 1 |
| 107 | -vasc-score | 1 |
| 108 | nonphytate | 9 |
| 109 | antigen/parasite | 1 |
| 110 | ultivite | 1 |
| 111 | paciente | 1 |
| 112 | sive | 1 |
| 113 | more-extensive | 1 |
| 114 | primitif | 1 |
| 115 | equivalents-eq-of | 1 |
| 116 | group-ag | 1 |
| 117 | ml.min-1.kg | 1 |
| 118 | sulphate/kg | 1 |
| 119 | nmole/mg | 1 |
| 120 | pmole/mg | 1 |
| 121 | adrenaline/30mg | 1 |
| 122 | difference-comparing | 1 |
| 123 | píng | 1 |
| 124 | group-rg | 1 |
| 125 | /pai | 1 |
| 126 | 4g/4g/pai | 1 |
| 127 | stabi | 1 |
| 128 | activi | 1 |
| 129 | hzi | 1 |
| 130 | hēi | 1 |
| 131 | -1/k | 1 |
| 132 | wps/week | 1 |
| 133 | nmol·min/l | 2 |
| 134 | ca-al | 1 |
| 135 | 10mg/kg/day+imidapril | 1 |
| 136 | gags/mmol | 1 |
| 137 | 4-hy-droxy-but-2-ynyl | 1 |
| 138 | metalaxyl-m | 1 |
| 139 | absolute/atm | 1 |
| 140 | ante-/post-partum | 1 |
| 141 | protein.in | 1 |
| 142 | post-triton | 1 |
| 143 | 3d/o | 1 |
| 144 | giacco | 1 |
| 145 | arsénio | 1 |
| 146 | haplo | 1 |
| 147 | -dimethylamino | 1 |
| 148 | loro | 1 |
| 149 | detection-to | 1 |
| 150 | procedimento | 1 |
| 151 | explantations/two | 1 |
| 152 | adaptação | 1 |
| 153 | tricam-p | 1 |
| 154 | h-clean-up | 1 |
| 155 | group=group | 1 |
| 156 | achievedafter | 1 |
| 157 | university-vancouver | 1 |
| 158 | rca-cfr | 1 |
| 159 | test.for | 1 |
| 160 | population.s | 1 |
| 161 | 80474-14-2/cas | 1 |
| 162 | glucose+lipids | 2 |
| 163 | deoxygenates | 1 |
| 164 | animais | 1 |
| 165 | anéis | 1 |
| 166 | regulans | 1 |
| 167 | recurrens | 1 |
| 168 | clevios | 1 |
| 169 | can48.00-dollars | 1 |
| 170 | melanoplus | 1 |
| 171 | isys | 1 |
| 172 | b-ht | 1 |
| 173 | chizukit | 1 |
| 174 | isrcnt | 1 |
| 175 | antagoinst | 1 |
| 176 | chepu | 1 |
| 177 | instru | 1 |
| 178 | 1/fv | 1 |
| 179 | fe3-x | 1 |
| 180 | vs.day | 1 |
| 181 | 446.2/day | 1 |
| 182 | a-poly | 2 |
| 183 | population♂×my | 1 |
| 184 | rectal-axillary | 1 |
| 185 | dihdyroxy | 1 |
| 186 | characteriz | 1 |
| 187 | invega® | 1 |
| 188 | 16″ | 1 |